tbc-11251 has been researched along with avosentan in 3 studies
| Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) | Studies (avosentan) | Trials (avosentan) | Recent Studies (post-2010) (avosentan) |
|---|---|---|---|---|---|
| 167 | 32 | 58 | 29 | 10 | 15 |
| Protein | Taxonomy | tbc-11251 (IC50) | avosentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.9 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0023 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolli, MH; Boss, C; Gatfield, J | 1 |
| Barton, M | 1 |
| Kohan, DE; Pollock, DM | 1 |
3 review(s) available for tbc-11251 and avosentan
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |
Endothelin antagonism and reversal of proteinuric renal disease in humans.
Topics: Endothelins; Humans; Isoxazoles; Kidney Diseases; Phenylpropionates; Proteinuria; Pyridines; Pyrimidines; Receptor, Endothelin A; Thiophenes | 2011 |
Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Isoxazoles; Kidney Failure, Chronic; Pyridines; Pyrimidines; Renal Dialysis; Renal Insufficiency, Chronic; Thiophenes; Treatment Outcome | 2013 |